Sekar Kathiresan, Chief Executive Officer - Verve Therapeutics (VERV)
Sekar Kathiresan is a prominent cardiologist and geneticist, renowned as the co-founder and CEO of Verve Therapeutics (NASDAQ: VERV), a biotechnology company focused on innovative gene-editing therapies for cardiovascular diseases.“At Verve, we strive to build the preeminent company developing gene-editing medicines to treat atherosclerotic cardiovascular disease (ASCVD). We are leveraging the expertise and capabilities of our team, whose singular focus is on addressing the root causes of this condition,” says Karthiresan.
Kathiresan graduated summa cum laude with a B.A. in History from the University of Pennsylvania in 1992 and earned his M.D. from Harvard Medical School in 1997. He completed his internal medicine and cardiology clinical training at Massachusetts General Hospital (MGH) and served as chief resident. His postdoctoral research training spanned from 2003 to 2008, focusing on cardiovascular genetics through collaborations at the Broad Institute and the Framingham Heart Study.
Before founding Verve Therapeutics in 2018, Kathiresan held several significant positions that shaped his career. He served as the Director of the MGH Center for Genomic Medicine, where he led groundbreaking research in genomics. Additionally, he was the Director of the Cardiovascular Disease Initiative at the Broad Institute, where he focused on advancing innovative approaches to cardiovascular health. Kathiresan also held the position of Professor of Medicine at Harvard Medical School, contributing to the academic community while mentoring the next generation of medical professionals.
As CEO, Kathiresan has made several key contributions to Verve Therapeutics, shaping the company’s vision and scientific direction. He has been instrumental in developing single-course gene-editing therapies to lower LDL cholesterol levels, critical for treating atherosclerotic cardiovascular disease. Verve Therapeutics’ approach seeks to provide long-lasting effects with a single treatment, contrasting with traditional lifelong medication regimens.
His research on genetic mutations that confer resistance to heart attacks has directly influenced the company’s therapeutic strategies, particularly by identifying specific genes that can be targeted to mimic the protective effects seen in individuals with naturally low cholesterol levels. This work has laid the groundwork for potential treatments to significantly reduce heart attack risk. Kathiresan’s research has also challenged established beliefs about cholesterol, including his pivotal study showing that high high-density lipoprotein (HDL) cholesterol levels do not necessarily correlate with a lower risk of heart attacks.
This finding has reshaped clinicians' understanding of HDL's role in cardiovascular health, prompting a paradigm shift that has influenced pharmaceutical strategies, particularly in developing HDL-raising treatments, many of which have not succeeded in clinical trials.
The implications of his discoveries extend beyond academic research; they are foundational to the mission of Verve Therapeutics, which aims to develop gene-editing therapies that can provide long-lasting protection against heart disease by targeting these identified genes. The goal is to create treatments that could eliminate the need for lifelong cholesterol-lowering medications.
This finding has reshaped clinicians' understanding of HDL's role in cardiovascular health, prompting a paradigm shift that has influenced pharmaceutical strategies, particularly in developing HDL-raising treatments, many of which have not succeeded in clinical trials.
The implications of his discoveries extend beyond academic research; they are foundational to the mission of Verve Therapeutics, which aims to develop gene-editing therapies that can provide long-lasting protection against heart disease by targeting these identified genes. The goal is to create treatments that could eliminate the need for lifelong cholesterol-lowering medications.
"At Verve, we strive to build the preeminent company developing gene-editing medicines to treat atherosclerotic cardiovascular disease (ASCVD). We are leveraging the expertise and capabilities of our team, whose singular focus is on addressing the root causes of this condition. "
Under Karthiresan’s leadership, Verve Therapeutics is advancing a pipeline of gene-editing medications, including VERVE-101, which targets the PCSK9 gene to lower cholesterol levels. This CRISPR-based approach is designed to permanently alter the genetic factors contributing to cardiovascular disease.
His contributions have been widely recognized with numerous prestigious awards, including the Distinguished Scientist Award from the American Heart Association, which honors his groundbreaking research in cardiovascular disease. He was also honored with the Curt Stern Award from the American Society of Human Genetics.
His work represents a significant advancement in cardiovascular genetics and offers promising avenues for preventing heart disease through genetic insights and innovative therapies. Through these contributions, Kathiresan is advancing the scientific understanding of cardiovascular disease and driving the development of transformative treatments that could change how this prevalent condition is treated.